Wantai Biopharma starts phase III trial for VZV-7D vaccine

Beijing Wantai Biological Pharmacy Enterprise (SSE:603392) announced the commencement of Phase III clinical trials for its freeze-dried varicella live attenuated vaccine (VZV-7D) and the completion of the first subject enrollment. The primary objective of the trial is to evaluate the protective efficacy, safety, and immunogenicity of VZV-7D in individuals aged 1-12 years. The vaccine utilizes a strain constructed with reverse genetics technology, aiming for enhanced safety by preventing skin infection and latent reactivation. While the company acknowledges competition from existing Oka-strain varicella vaccines, it emphasizes the inherent uncertainties of clinical trials and market acceptance, advising investors to exercise caution.